Amina Jindani, Thomas S Harrison, Andrew J Nunn, Patrick P J Phillips, Gavin J Churchyard, Salome Charalambous, Mark Hatherill, Hennie Geldenhuys, Helen M McIlleron, Simbarashe P Zvada, Stanley Mungofa, Nasir A Shah, Simukai Zizhou, Lloyd Magweta, James Shepherd, Sambayawo Nyirenda, Janneke H van Dijk, Heather E Clouting, David Coleman, Anna L E Bateson, Timothy D McHugh, Philip D Butcher, Denny A Mitchison
BACKGROUND: Tuberculosis regimens that are shorter and simpler than the current 6-month daily regimen are needed. METHODS: We randomly assigned patients with newly diagnosed, smear-positive, drug-sensitive tuberculosis to one of three regimens: a control regimen that included 2 months of ethambutol, isoniazid, rifampicin, and pyrazinamide administered daily followed by 4 months of daily isoniazid and rifampicin; a 4-month regimen in which the isoniazid in the control regimen was replaced by moxifloxacin administered daily for 2 months followed by moxifloxacin and 900 mg of rifapentine administered twice weekly for 2 months; or a 6-month regimen in which isoniazid was replaced by daily moxifloxacin for 2 months followed by one weekly dose of both moxifloxacin and 1200 mg of rifapentine for 4 months...
October 23, 2014: New England Journal of Medicine